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Differentiation of precursor into specialized cells involves an increasing restriction in proliferative capacity,
culminating in cell cycle exit. In this report we used a human neuroblastoma cell line to study the molecular
mechanisms that coordinate cell cycle arrest and neuronal differentiation. Exposure to retinoic acid (RA), a
differentiation agent in many cell types, causes an upregulation of neurotrophin receptor TrkB and the cyclin
kinase inhibitor p21Cip1 at a transcriptional level. Full transcriptional activation of these two genes requires
canonical E-box sequences found in the TrkB and p21Cip1 promoters. As reported for other E-box-regulated
promoters, ectopic expression of E47 and E12 basic helix-loop-helix (bHLH) proteins enhances RA-dependent
expression of TrkB and p21Cip1, whereas the inhibitory HLH Id2 exerts opposite effects. In addition, ectopic
expression of E47 and NeuroD, a neuronal bHLH protein, is able to activate TrkB transcription in the absence
of RA. More importantly, we show that E47 and NeuroD proteins bind the TrkB and p21Cip1 promoter
sequences in vivo. Since they establish a direct transcriptional link between a cell cycle inhibitor, p21Cip1, and
a neurotrophic receptor, TrkB, bHLH proteins would play an important role in coordinating key events of cell
cycle arrest and neuronal differentiation.
Cell differentiation is a coordinated process that comprises
cell cycle exit and a specific gene expression program to deter-
mine tissue identity. Many studies have provided knowledge
about the molecules involved in cell cycle arrest and the key
regulatory transcription factors that control tissue specific gene
expression (22, 27).
The basic helix-loop-helix (bHLH) proteins are transcrip-
tion factors that regulate gene expression to promote cell dif-
ferentiation and tissue-specific cellular functions (54). For
instance, NeuroD and neurogenins (Ngn1 and Ngn2) are tis-
sue-specific bHLH proteins involved in neurogenesis (28).
These tissue-specific proteins form dimers with other ubiqui-
tously expressed bHLH transcription factors called E proteins,
which bind to the canonical E-box sequence CANNTG and
include HEB, E2-2, and the E2A gene products, E12 and E47
(28). In addition, the activity of bHLH proteins as transcription
factors is negatively regulated by the structurally related Id
proteins (inhibitors of DNA binding and/or differentiation)
(37). Id proteins possess the HLH domain, through which they
form dimers, mainly with E proteins. As a result, E proteins
cannot form functional heterodimers with the tissue-specific
bHLH factors, leading to inhibition of differentiation (37). Id
proteins are involved not only in cell differentiation control but
also in the regulation of cell proliferation. Based on in vivo (20,
27, 33) and in vitro (13, 19, 42) experiments, two mechanisms
have been proposed to explain how Id proteins contribute to
cell cycle entry. One mechanism involves the downregulation
of cyclin-dependent kinase inhibitors at a transcriptional level,
where Id proteins would interfere with bHLH-driven expres-
sion of p16Ink4a, p27Kip1, and p21Cip1 (27, 33). The other pro-
posed mechanism involves Id protein interaction with the tu-
mor suppressor retinoblastoma protein (pRb). Id2 has been
shown to bind the unphosphorylated pRb through interaction
between the HLH region and the pocket domain of the re-
spective proteins, resulting in the release of E2F (13, 20).
Neuroblastoma is a pediatric solid tumor derived from crest
precursor cells (3). Cell lines and tumors from patients with a
poor prognosis are associated with expression of the neurotro-
phin BDNF (for brain-derived neurotrophic factor) and its
tyrosine kinase receptor TrkB (2, 35). Several studies indicate
that BDNF increases neuroblastoma cell survival, neurite ex-
tension, and cell invasion and protects cells from chemother-
apy (6, 14, 25, 29, 32). This indicates that, aside from being a
marker of poor prognosis, BDNF and TrkB play a role in the
biology of neuroblastoma tumors. Thus, understanding the
molecular mechanisms that regulate TrkB expression may pro-
vide tools to block the ability of BDNF to rescue cells from
chemotherapy (14, 47). Little is known about the mechanisms
by which TrkB is regulated. Alternative splicing within the
TrkB intracellular domain has been shown to generate iso-
forms with truncated or full kinase domain (18), which may
have distinct signaling capabilities and cellular responses to the
neurotrophins (45). With regard to the existence of regulatory
elements in the TrkB promoter, a recent report demonstrates
that in the developing rat brain, thyroid hormone downregu-
lates TrkB expression through a novel response element lo-
cated downstream of the transcription initiation site (41).
Retinoic acid (RA) plays important roles in neural develop-
mental (43), and retinoid therapy significantly improves the
survival in patients with acute promyelocytic leukemia or neu-
roblastoma tumors. In a previous study (5) we have shown that
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in SH-SY5Y cells, a human neuroblastoma cell line, RA treat-
ment induces a neuronal differentiation process, with a con-
comitant G1 arrest and the accumulation of hypophosphory-
lated pRb forms, increased expression of TrkB and other
neuronal markers, and extension of neuritic processes. More-
over, RA treatment yields a homogeneous population of dif-
ferentiated cells, which strictly depends on BDNF for their
survival, thus behaving in this respect as primary neurons (5).
Here we show that transcriptional activation of p21Cip1 by
RA depends on E-box sequences. Full activation of p21Cip1 is
simultaneous to the activation of TrkB expression, which also
depends on canonical E-box sequences. E2A proteins enhance
the expression of TrkB and p21Cip1, whereas Id2 exerts oppo-
site effects, and ectopic expression of E47 and NeuroD is able
to activate TrkB transcription in the absence of RA. More
important, we show for the first time that E47 and NeuroD
proteins bind both the TrkB and the p21Cip1 promoters. Thus,
these bHLH proteins establish a direct transcriptional link
between molecules involved in the regulation of cell cycle and
neuronal differentiation, which should help to tightly coordi-
nate these two processes.
MATERIALS AND METHODS
Cell culture. SH-SY5Y neuroblastoma cells were grown at 37°C in a humid-
ified atmosphere of 5% CO2 in Dulbecco modified Eagle medium (DMEM;
Gibco) supplemented with 2 mM L-glutamine, 20 U of penicillin/ml, 20 mg of
streptomycin/ml, and 15% fetal calf serum (Gibco). To induce cell cycle arrest
and differentiation, all-trans-RA (Sigma) was added to a final concentration of 10
M. The medium was changed every 3 days. For data regarding the expression
of GAP43 (see Fig. 6B), cells treated for 2 days with RA were washed three times
with DMEM (without serum) and incubated for 6 h with 20 ng of BDNF/ml in
DMEM (without serum).
Plasmid constructions. The Id2 expression plasmid was constructed by cloning
the BamHI-HindIII fragment containing the complete human Id2 coding se-
quence into pcDNA3 (Invitrogen). The expression plasmids pCMV-E12 and
pCMV-E47 containing the full-length cDNAs encompassing the respective cod-
ing regions of human E12 and E47 into pcDNA3 vector were a generous gift
from M. Nakamura (9). The p21Cip1 luciferase reporter construct carries a 2.3-kb
fragment from positions 2296 to 22 relative to the transcription start site of
the human p21Cip1 promoter into the KpnI-XhoI site of pGL3-Basic (pGL3b)
vector (Promega). A 1.9-kb fragment from positions1888 to30 relative to the
main transcription start site of human TrkB promoter was inserted into the
KpnI-BamHI site of pGL3b, generating the TrkB luciferase reporter construct.
TrkB and p21Cip1 promoter E-box and RARE mutants were produced by site-
directed mutagenesis by using the transformer site directed mutagenesis kit
(Clontech). The construct with the p21Cip1 E-box region contains sequences from
positions 212 to 30 of the p21Cip1 promoter. Three E-box consensus se-
quences (TCTGGGCCATCTGCTGATCC) were cloned into the pGL3 pro-
moter (pGL3p) vector (Promega) to create the synthetic E-box reporter con-
struct. To create FLAG-E47(1-651) and FLAG-NeuroD(1-356) expression
vectors, the indicated coding regions were amplified from cDNA templates by
PCR and inserted into the BamHI/EcoRI site of a modified pcDNA3 plasmid
containing three copies of the FLAG epitope. Detailed procedures used to
generate these constructions are available upon request.
Flow cytometry analysis. Cells were harvested by treatment with trypsin and
resuspension in 1 ml of cold PBS, followed by incubation with 1 ml of 0.1%
Triton X-100, 50 g of propidium iodide/ml, and 50 g of RNase/ml for 30 min
on ice before analysis on an EPICS XL flow cytometer (Coulter).
Western blotting and immunoprecipitation. Cells were washed with PBS three
times, lysed in 2% sodium dodecyl sulfate (SDS), 125 mM Tris-HCl (pH 6.8),
sonicated and boiled for 5 min. The protein concentration was determined by a
Micro- DC protein assay (Bio-Rad). Immunoblot analysis was carried out as
previously described (5). The following antibodies were used at the dilutions
recommended by the manufacturers: anti-Cdk4 (-Cdk4; 06-139; Upstate),
-Cdk2 (06-505; Upstate), -Cdk1 (06-194; Upstate), -cyclin D1 (06-137; Up-
state), -cyclin E (06-459; Upstate), -p21Cip1 (05-345; Upstate), -p53 (05-224;
Upstate), -p27Kip1 (610241; Transduction Laboratories), -tubulin (T5168;
Sigma), -p18Ink4c (NA55; Oncogene Research Products), -p57Kip2 (65021A;
Pharmingen), -pRB (554136; Pharmingen), and -E47 (sc-763; Santa Cruz
Biotechnology). Cdk2 and Cdk4 were immunoprecipitated as described previ-
ously (31).
RNA extraction, real-time RT-PCR, and Northern analysis. Total cellular
RNA preparation and reverse transcription (RT) were carried out as described
previously (4). Quantitative real-time PCR analysis was performed with Applied
Biosystems TaqMan Universal PCR Master Mix according to manufacturer
instructions. Triplicate reactions for each sample were done in a 96-well optical
reaction plate for human p21Cip1 (4318364T MGB probe with FAM reporter
label), human TrkB (Hs001778811 m1 MGB probe with FAM reporter label),
and human GAPDH (4326317E MGB probe with VIC reporter label). Samples
were run and analyzed with a Icycler iQ real-time detection system (Bio-Rad).
Northern blot assay was performed as previously reported (10).
Luciferase assays. Transfection was accomplished with Lipofectamine 2000
(Invitrogen). Unless otherwise indicated, luciferase assays during RA treatment
were performed as follows: SH-SY5Y cells were plated in medium with 10 M
RA, in triplicate, at 6.5  104 cells in 24-well plates for 3 days and then
transfected and maintained in RA for 48 to 96 h before luciferase activity was
determined with the Dual Luciferase reporter assay system (Promega). Firefly
luciferase activity was made relative to Renilla luciferase activity. Routinely, 1.1
g of firefly luciferase reporter plasmid and 0.1 g of pRL-TK plasmid (Pro-
mega), which contains the Renilla luciferase gene as an internal control, were
used to determine normalized gene expression values. To assess effects due to
E12, E47, or Id2, 0.2 g of corresponding expression plasmids or empty vector
was added in each transfection assay. Activation was estimated by the luciferase
activity in RA-treated cells relative to untreated cycling cells. The results shown
are the means and standard deviations of three independent transfection exper-
iments.
Immunofluorescence. Immunofluorescence was performed as previously de-
scribed with minor modifications (5). Cells were treated with 10 M RA for 4
days and then cotransfected with pEGFP-N1 (Clontech) and Id2 expression
plasmid or pcDNA3 with Lipofectamine 2000. At 24 h after transfection, cells
were incubated with 10 M bromodeoxyuridine (BrdU) for 4 h at 37°C, fixed in
4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in PBS for 10
min at room temperature. Cells were then treated with 50 g of DNase I
(Roche)/ml at 37°C for 30 min, incubated with a mouse monoclonal -BrdU
antibody (1:20 dilution; Molecular Probes) for 1 h at room temperature, and
subsequently incubated with an anti-mouse Alexa-546-labeled antibody (1:200
dilution; Molecular Probes) for 45 min at room temperature. Cells were coun-
terstained with DAPI (4,6-diamidino-2-phenylindole) before examination un-
der a fluorescence microscope, and a minimum of 1,000 cells were evaluated for
each transfection experiment.
ChIP assay. Formaldehyde was added at a final concentration of 1% directly
to SH-SY5Y cells either during cycling or after 5 days of RA treatment. Fixation
proceeded at 37°C for 10 min and was stopped by the addition of glycine to a final
concentration of 0.125 M. Cells were rinsed twice with ice-cold PBS, collected
into lysis buffer (50 mM Tris-HCl [pH 8.1], 10 mM EDTA, 1% SDS) with a
protease inhibitor cocktail (Sigma), incubated on ice for 10 min, and sonicated to
shear the chromatin to an average size of600 bp, followed by centrifugation for
30 min. Supernatants were collected and diluted 1:10 in buffer A (16.7 mM
Tris-HCl [pH 8.1], 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100, 0.01%
SDS, protease inhibitor cocktail) and precleared with protein A-Sepharose beads
for 4 h at 4°C. Samples of total chromatin were taken at this point as positive
control samples for PCR (input chromatin). Immunoprecipitation was per-
formed overnight at 4°C with 5 g of -E47 antibody (sc-763, Santa Cruz
Biotechnology, a polyclonal -E-47 antibody that also cross-reacts with E12).
Although a successful chromatin immunoprecipitation (ChIP) experiment has
been recently reported with a monoclonal -E47 antibody on the pT alpha gene
promoter (49), the polyclonal antibody used gave higher signal-noise ratios
under our conditions (data not shown). DNA-protein complexes were collected
with protein A-Sepharose beads and washed four times: once with 50 mM
Tris-HCl (pH 8.0)–2 mM EDTA–0.2% Sarkosyl, twice with 100 mM Tris-HCl
(pH 9.0)–500 mM LiCl–1% NP-40–1% sodium deoxycholate, and once with
Tris-EDTA buffer. Precipitates were extracted twice with lysis buffer. Eluates
were pooled, diluted 1:10 in buffer A, and immunoprecipitated again as de-
scribed above. Final eluates were adjusted to 0.3 M NaCl and 50 g of RNase
A/ml, followed by incubation overnight at 65°C. Samples were then extracted
with phenol-chloroform, and precipitated overnight with ethanol in the presence
of 20 g of glycogen as carrier. Immunoprecipitated material was used as a
template for PCR amplification. The primers 5-TGATTAGAAAGTAGGA
CCGC and 5-CTGTCTTGTCAGTGAACCTT were used to amplify a 337-bp
region of the TrkB promoter; the primers 5-CGAAGTCAGTTCCTTGTGGA
VOL. 24, 2004 bHLH PROTEINS LINK TrkB AND p21Cip1 EXPRESSION 2663
 o
n
 January 6, 2014 by W








and 5-ACATCCCGACTCTCGTCAC were used to amplify a 292-bp region of
the p21Cip1 promoter. The primer set used to amplify the promoter region of L27
was as described previously (4).
For ChIP with tagged proteins (see Fig. 5D), cells were treated with 10 M RA
for 2 days and then transfected with pcDNA3 (as a control) or expression vectors
FLAG-E47 and FLAG-NeuroD with Lipofectamine 2000. At 72 h after trans-
fection, cells were fixed for ChIP assay as described above with some modifica-
tions. Lysates were first immunoprecipitated with -E47 antibody (sc-763; Santa
Cruz Biotechnology), and the eluates were subjected to a second round of
immunoprecipitation with -Flag M2 agarose beads (F3165; Sigma). The prim-
ers 5-GTTACGGTTTGTCACCCGAC and 5-TTCCCAGATCGTGGAT
TCAC were used to amplify a 260-bp region of the TrkB promoter. To amplify
the promoter region of p21Cip1 and L27, we used the same primer set as de-
scribed above.
RESULTS
RA triggers mechanisms to promote cell cycle arrest. In a
previous study (5), we reported that RA induces cell cycle
arrest and promotes differentiation in SH-SY5Y cells. To study
the mechanism triggered by RA to induce these two processes,
we monitored the expression of genes involved in the regula-
tion of cell cycle progression and differentiation. Accordingly
with the observed withdrawal from the cell cycle, RA treat-
ment for 5 days caused an accumulation of the hypophosphor-
ylated forms of pRb (6) (Fig. 1A), suggesting that cyclin D- and
cyclin E-associated kinase activities could be downregulated.
However, SH-SY5Y cells maintained invariable levels of D-
and E-type cyclins after RA treatment compared to untreated
cycling cells (Fig. 1A). The amount of the catalytic subunits
Cdk4 and Cdk2 was not affected either by RA treatment,
indicating that RA does not regulate these Cdk activities at
transcriptional or translational levels in SH-SY5Y cells. We
next decided to test whether the accumulation of hypophos-
phorylated pRB during RA-induced cell cycle arrest could be
mediated by Cdk inhibitors. Regarding the KIP family of Cdk
inhibitors, RA treatment caused a twofold increase in p27Kip1
and a tenfold increase in p21Cip1 protein levels, whereas the
amount of p57Kip2 remained constant. The only inhibitor of the
INK family that we were able to detect in SH-SY5Y cells was
p18INK4c, which remained also constant during RA treatment.
As seen in Fig. 1B and C, a comparable increase in Cdk4- and
Cdk2-bound p21Cip1 was also observed in RA-treated cells. On
the other hand, although the level of p27Kip1 associated with
Cdk2 was unaffected by RA treatment, the amount bound to
Cdk4 showed an important increase, a finding which suggests
the existence of unequal redistribution mechanisms driven by
RA treatment. Taken together, these results suggest that the
accumulation of hypophosphorylated pRb species in SH-SY5Y
cells could be due to the direct inhibition of cyclin-Cdk com-
plexes mediated by the increase of p21Cip1 levels observed after
treatment with RA.
Regulation of TrkB and p21Cip1 expression by RA treatment.
Our finding that p21Cip1 expression is activated by RA agrees
with previous studies with other cell types (11). It is known that
the p21Cip1 promoter has a functional RA-responsive element
localized between bp1212 and1194 (11). If we assume that
the observed induction of p21Cip1 was due to the binding of the
RA receptor (RAR) to the RA response element (RARE) in
the p21Cip1 promoter, we would expect to have an early re-
sponse of p21Cip1 expression, since it has classically been de-
scribed for signaling mechanisms directly mediated by nuclear
receptors such as RAR (39). To test this possibility, we per-
formed a time course experiment to determine the kinetics of
p21Cip1 expression. Figure 2A and B shows that p21Cip1 expres-
sion increased in a stepwise manner. During the first 6 h of RA
treatment, the expression of p21Cip1 showed an early although
moderate (2-fold) induction. A second induction burst was
observed at between 24 and 48 h of RA treatment, which
caused an overall increase of 10-fold in p21Cip1 expression
levels, and remained constant during the remaining period
analyzed. Changes in p21Cip1 protein followed the levels of the
p21Cip1 transcript, suggesting that p21Cip1 is upregulated
mainly by transcriptional mechanisms when cells are subjected
to RA treatment. As observed in other differentiation models
in which a p21Cip1 induction has been described (1, 34, 55), the
levels of p53 remained constant (Fig. 2B), and the protein was
localized in the cytoplasm during RA treatment (data not
shown), making the direct participation of p53 in the transcrip-
tional upregulation of p21Cip1 by RA treatment unlikely. In a
time course analysis, we found that pRb phosphorylation de-
creased only after 48 h of treatment with RA (Fig. 2B), cor-
relating with the second burst of p21Cip1 expression. Thus, the
first increase of p21Cip1 expression was unable to inhibit pRb
phosphorylation significantly. Moreover, as seen in Fig. 2C, the
proportion of cells in S phase started to decrease only after 2
days in RA, suggesting that cell cycle arrest would only be
achieved when cells reached high levels of p21Cip1 expression,
as a consequence of the second upregulation step.
It has been reported that RA induces the expression of TrkB
in SH-SY5Y cells, making them responsive to BDNF (15).
TrkB is a neuron-specific gene that codes for the receptor of
FIG. 1. RA modifies expression levels of genes involved in cell
cycle control in SH-SY5Y cells. Cells either cycling (cyc) or treated for
5 days with RA (5d RA) were analyzed. (A) Western blot of cell cycle
regulatory proteins; (B and C) p21Cip1 and p27Kip1 levels in Cdk4 and
Cdk2 immunoprecipitates, respectively.
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neurotrophin BDNF and is expressed during the final steps of
neuronal differentiation. However, the molecular mechanisms
involved in the transcriptional activation of TrkB during neu-
ronal differentiation are unknown. Since we were also inter-
ested in studying the coordination of cell cycle arrest and
differentiation induced by RA treatment, we monitored the
expression levels of TrkB by real-time RT-PCR in a time
course experiment. Figure 2D shows that the upregulation of
TrkB expression takes place 48 h after RA treatment, clearly
later than the first burst of p21Cip1 induction. Since the TrkB
promoter sequence does not show any canonical RA-receptor
binding sites, these data suggest that RA may use different
early and late mechanisms to induce expression of p21Cip1 and
TrkB. The first induction of p21Cip1 expression could be di-
rectly mediated by the RA receptor as an early event, whereas
the mechanisms involved in the second burst of p21Cip1 and the
induction of TrkB expression could be intrinsically different
from those causing the early response.
E2A proteins mediate transcriptional activation of TrkB and
p21Cip1. To understand the mechanism by which RA induces
TrkB expression at the same time that full induction of p21Cip1
occurs, we sought to determine whether other known DNA
binding elements, different from the RAR site, could partici-
pate in this transcriptional regulation. It is known that bHLH
proteins are involved in the upregulation of p21Cip1 transcrip-
tion during muscle and enteroendocrine cell differentiation
(36). It has been shown by electrophoretic mobility shift assay
that bHLH proteins bind the E-box elements located within
180 bp upstream from the start site of the p21Cip1 promoter
(42). On the other hand, the human TrkB promoter sequences
show three canonical E-box sequences located at bp 16,
236, and 820 relative to the transcription start site of TrkB.
To test whether E-box sequences could mediate full induction
of p21Cip1 and TrkB gene expression during RA treatment,
luciferase-based reporter constructs containing wild-type and
mutant versions of the respective promoter regions (Fig. 3A)
were assayed by transfection in SH-SY5Y cells. As expected,
normalized luciferase activities obtained from wild-type
p21Cip1 and TrkB promoters showed a fivefold increase when
RA-treated versus untreated cycling cells were compared (Fig.
3B). Supporting a direct role of RA on p21Cip1 expression,
normalized luciferase activities obtained with a p21Cip1 pro-
moter mutant lacking the RA-receptor binding site remained
nearly constant after RA treatment. More importantly, point
mutations targeting the E-box sequences almost abolished the
activation caused by RA in both p21Cip1 and TrkB promoters
(Fig. 3B). Thus, E-box sequences seem to play an essential role
in the transcriptional response of these two genes during RA
treatment. Supporting this idea, Fig. 3C shows that a lucif-
erase-based reporter construct driven by three copies of a
synthetic E-box sequence showed a twofold activation by RA
treatment. Since point mutations in either the RARE or E-box
sequences of the p21Cip1 promoter cause strong effects in the
FIG. 2. Effects of RA in a time course experiment. (A) Expression
levels of p21Cip1 analyzed by Northern blotting. GAPDH mRNA is
shown as loading control. (B) Western blot of p21 and p53. The state
of phosphorylation of pRB is shown at the bottom. Westerns blots
were reprobed with antibody against tubulin as loading control.
(C) DNA content distributions during RA treatment. Percentages of
cells in S phase during RA treatment are shown. (D) Expression levels
of p21Cip1 and TrkB analyzed by real-time RT-PCR in three indepen-
dent experiments. Average values and standard deviations are shown.
GADPH was coamplified in the same RT-PCR as an internal control.
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transcriptional response to RA, it suggests the existence of
cooperative effects between the RA receptor and bHLH pro-
teins on the full p21Cip1 promoter. This cooperative effect
should involve other elements besides RARE and E-box ele-
ments, since a construct that only contains the E-box region of
the p21Cip1 promoter is almost as active as the wild-type pro-
moter (Fig. 3C). Taken together, these data suggest that E-box
sequences may be the common elements in p21Cip1 and TrkB
promoters essential for RA to cause a full transcriptional ac-
tivation.
E2A proteins have been found to stimulate p21Cip1 expres-
sion in several cell lines, and it has been shown that E-box
sequences mediate this activation (9, 42). On the other hand,
Id proteins are negative regulators of bHLH proteins, and it
has been shown recently that RA treatment causes a transcrip-
tional downregulation of Id genes in SH-SY5Y cells (24). To
determine whether these proteins regulate the expression of
TrkB, we examined the effects of Id2 and the E2A gene prod-
ucts, E12 and E47, on TrkB promoter activity. In parallel, we
checked the expression of p21Cip1 under the same experimen-
tal conditions. SH-SY5Y cells were incubated for 3 days with
RA and cotransfected with TrkB or p21Cip1 transcriptional
reporter constructs, with the addition of Id2 or E2A expression
plasmids (pCMV-E12 or pCMV-E47), and then normalized lu-
ciferase activities were determined after 4 days of culture with
RA (Fig. 4A). Overexpression of E12 and E47 further in-
creased RA-dependent activation of the TrkB promoter by a
factor of 2. Similarly, the p21Cip1 promoter was further acti-
vated by the ectopic expression of E12 and E47, although the
magnitude of activation was lower compared to the TrkB pro-
moter. Figure 4A also shows that Id2 overexpression clearly
impaired the transcriptional activation of TrkB and p21Cip1
promoters by RA. Moreover, we observed that cells subjected
to Id2 overexpression incorporated significantly more BrdU
FIG. 3. Transcriptional activation of p21Cip1 and TrkB by RA requires E-box elements. (A) Schematic representation of the p21Cip1 and TrkB
promoter fusions to luciferase used in the present study (see Materials and Methods), showing wild-type and mutated E-box and RARE regulatory
sequences. (B) Transcriptional activation of the p21Cip1 and TrkB promoter constructs by RA. Normalized expression levels produced by the
respective promoter constructs after 5 days of RA treatment were made relative to those obtained in cycling cells. Average values and standard
deviations obtained from three independent transfection experiments are shown. (C) Transcriptional activation driven by a three synthetic E-box
construct (E-box synthetic), the wild-type p21Cip1 promoter, and a shorter fragment of the p21Cip1 promoter containing the E-box elements (p21Cip1
E-box region) in cells treated with RA for 5 days. Normalized expression levels were obtained as in panel B.
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FIG. 4. E2A and Id2 proteins modulate TrkB and p21Cip1 promoter activity in RA-treated cells. (A) TrkB () and p21Cip1 (u) promoter
constructs used in Fig. 3 were cotransfected with E12, E47, and Id2 expression vectors or the empty vector. Normalized expression levels produced
by the respective promoter constructs after 7 days of RA treatment were made relative to those obtained in cycling cells. Average values and
standard deviations obtained from three independent transfection experiments are shown. (B) BrdU incorporation as shown by immunofluores-
cence after 5 days of treatment with RA. Cells were cotransfected with a transfection reporter GFP plasmid and the Id2 expression vector (top
panel) or the empty vector (bottom panel). Although some BrdU incorporation was observed in GFP-negative cells in both panels (see arrow in
lower panel), cells positive for both BrdU incorporation and GFP expression were much more frequent if the Id2 expression plasmid was added
(arrows in upper panel). (C) Quantification of the BrdU incorporation shown in panel B. As indicated in Materials and Methods, cells were
counterstained with DAPI, and a minimum of 1,000 cells were evaluated in each transfection. The graph shows the percentages of BrdU-positive
cells relative to GFP-positive cells.
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compared to control cells (Fig. 4B and C). These results sug-
gest that the E2A products, E12 and E47, induce TrkB and
p21Cip1 promoter activity in SH-SY5Y cells during RA treat-
ment, whereas, in addition to its role in pRB inhibition, Id2
could act as a positive regulator of the cell cycle machinery by
inhibiting bHLH-driven expression.
E2A proteins and NeuroD bind the TrkB promoter in RA-
treated cells. To test whether E2A proteins bind to the pro-
moter region of TrkB in vivo, we performed ChIP assays with
a polyclonal -E47 antibody that also cross-reacts with E12
protein in RA-treated cells and untreated cycling cells. As
shown in Fig. 5A, the -E47 antibody, but not normal immu-
noglobulin G, was able to immunoprecipitate the TrkB pro-
moter sequences in both RA-treated and untreated cells. In
addition, immunoprecipitation of the TrkB promoter se-
quences was specific since DNA from the ribosomal gene L27
included as a control was efficiently removed during the dou-
ble-immunoprecipitation steps of the procedure used for ChIP.
After the TrkB and L27 PCR products were normalized to
those obtained in input samples, immunoprecipitation of the
TrkB promoter from RA-treated cell extracts was found to be
approximately six times more efficient than that obtained from
untreated cell extracts.
Although the E47 protein has been involved in transcrip-
tional regulation of p21Cip1 in other models, molecular proof of
a direct implication in vivo was still missing. Thus, we also
carried out a ChIP assay with the -E47 antibody on the
p21Cip1 promoter in SH-SY5Y cells and obtained positive re-
sults (Fig. 5A). Normalized immunoprecipitation efficiencies
of the p21Cip1 promoter were also higher (about three times
higher) in RA-treated cell extracts compared to untreated cell
extracts (Fig. 5A). Since the levels of E2A proteins were very
similar in both RA-treated and untreated cells (Fig. 5B), these
data suggest that the presence of E2A proteins on the p21Cip1
promoter may be enhanced by RA treatment. The differences
in the two promoters regarding the relative increase of ChIP
efficiencies in RA-treated compared to cycling cells may be
related to the fact that transcriptional control of TrkB expres-
sion is much tighter compared to p21Cip1. To confirm these
results, we carried out a ChIP assay in RA treated cells tran-
siently expressing a Flag-tagged E47 protein (see Fig. 5C). As
shown in Fig. 5D, both TrkB and p21Cip1 promoter sequences
were clearly enriched compared to control samples of cells
transfected with an empty vector.
Different lines of evidence suggest that NeuroD could act as
partner of E2A proteins in the upregulation of TrkB. First,
inner-ear sensory neurons from NeuroD-null mice fail to ex-
press TrkB and TrkC (17). Second, RA has been shown to
increase NeuroD expression in both SH-SY5Y cells (24) and
neural stem cells from adult rat hippocampus (46). Since two
commercially available antibodies raised against NeuroD did
not efficiently immunoprecipitate NeuroD under ChIP condi-
tions (data not shown), we decided to use a Flag-tagged
NeuroD protein (see Fig. 5C). In order to minimize the over-
expression effects due to transient transfection of the Flag-
NeuroD construct, cross-linked cell extracts were subjected to
the polyclonal -E47 antibody in a first immunoprecipitation
round and to -Flag beads in the second immunoprecipitation
step. In this way we should only detect promoter sequences not
only bound by overexpressed NeuroD but also by endogenous
FIG. 5. bHLH proteins bind the TrkB and p21Cip1 promoters in
vivo. (A) Cells either cycling or treated for 5 days with RA were
processed for ChIP with a polyclonal -E47 antibody. A dummy af-
finity-purified IgG was used as control in extracts obtained from RA-
treated cells. Input material and immunoprecipitates were analyzed by
PCR with oligonucleotide primers specific for the TrkB and p21Cip1
promoters (see Materials and Methods). L27 was coamplified in the
same PCR as the internal negative control. (B) E47 levels were deter-
mined by Western blot in the same samples taken as in panel A.
(C) For ChIP with -FLAG agarose beads, SH-SY5Y cells were trans-
fected with empty vector as a negative control or vectors encoding
FLAG-E47 and FLAG-NeuroD, which were analyzed by Western
blotting to detect ectopically expressed proteins. (D) Cells transfected
with vectors as in panel C were treated with RA for 5 days prior to the
ChIP assay. Lysates were immunoprecipitated with an -E47 antibody
(a polyclonal -E47 antibody that cross-reacts with E12), and eluates
were subjected to a second round of immunoprecipitation with
-FLAG M2 agarose beads (see Materials and Methods for details).
L27 was coamplified in the same PCR as the internal control.
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levels of E2A proteins. As shown in Fig. 5D, the results ob-
tained by competitive PCR strongly suggest that NeuroD is
present with E2A proteins on both the TrkB and p21Cip1 pro-
moters.
To test the functional relevance of these interactions, we
sought to determine whether ectopic expression of E47 and
NeuroD could increase the endogenous expression levels of
p21Cip1 and TrkB in the absence of RA. Since the p21Cip1 gene
is already expressed in cycling cells, small increases over the
basal level on a fraction of cells (we routinely obtain 20 to 30%
of transfected cells as assayed by green fluorescent protein
[GFP] coexpression) would be difficult to detect. Instead, TrkB
mRNA is almost undetectable in SH-SY5Y cycling cells (see
Fig. 2D). For this reason we decided to test by real-time PCR
whether TrkB expression levels could be upregulated by ec-
topic E47 and NeuroD in the absence of RA and 6 h after RA
addition. As shown in Fig. 6A, a minor but reproducible effect
was observed when cycling cells were transfected with E47 or
E47 plus NeuroD. Nonetheless, the relative difference in-
creased when cells were treated for 6 h with RA prior to
sample collection for real-time PCR, which suggests that RA
may exert posttranslational effects on the activity of these
bHLH proteins. Finally, Fig. 6B shows that ectopic expression
of E47 or E47 plus NeuroD enhanced the transcriptional ac-
tivation of GAP43 in a BDNF-dependent manner (4). Taken
together, these results strengthen the notion that E2A and
NeuroD bHLH proteins are key activators of TrkB expression.
DISCUSSION
Terminal differentiation of many tissues and cell types in-
volves an initial phase of growth and division of precursor cells
and a subsequent process of differentiation and withdrawal
from the cell cycle. Precise regulation of the timing of these
processes is very important to ensure the production of a
proper number of differentiated cells at an appropriate time. A
variety of observations in primary cultures support a role for
RA in neuronal differentiation. When hippocampus-derived
stem cells are exposed to RA, the expression of neurotrophin
receptors is upregulated (46). The sequential addition of RA
and BDNF or NT-3 to these cells leads to a significant increase
in the number of mature neurons generated. In vitro studies
with embryonic stem (ES) cells demonstrated that RA was able
to drive ES cell differentiation to a neuronal cell type. As
would be expected in vivo, neuronal determination depended
on the developmental stage at which they were treated with
RA, suggesting that differentiation signals are specifically in-
terpreted as a function of time during development (43). These
and other observations (16, 30) suggest that RA may be in-
volved in the acquisition of a neuronal fate and that collabo-
FIG. 6. Induction of endogenous TrkB by bHLH proteins. (A) SH-SY5Y cells were transfected with empty vector or vectors encoding E47 and
NeuroD. Transfected cells cycling (cyc) or treated for 6 h (6 h RA) with RA were used to analyze the expression levels of TrkB by real-time
RT-PCR. Average values and standard deviations obtained from three independent transfection experiments are shown. (B) GAP43 expression
analyzed by RT-PCR. Transfected cells as in panel A were treated for 2 days with RA and then stimulated or not with BDNF cultured for 6 h in
serum-free medium. L27 was coamplified in the same PCR as an internal control. The primer set used to amplify the promoter region of GAP43
and L27 were as described previously (4). (C) Scheme showing functional interactions between elements involved in controlling cell cycle and
differentiation. Asterisks mark major contributions of the present study (see Discussion for details).
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rative effects between RA and neurotrophins may be needed to
achieve a fully developed neuronal phenotype. The human
neuroblastoma cell line SH-SY5Y has proven to be a valuable
model for studying the effects of RA on neuronal differentia-
tion, including extension of neuritic processes, expression of
the TrkB receptor, and development of an enhanced choline
acetyltransferase activity (5, 15, 38).
Here we show that (i) RA activates expression of both TrkB
and p21Cip1 at a transcriptional level; (ii) full transcriptional
activation of these two genes require the E-box sequences
found in the TrkB and p21Cip1 promoters; (iii) E47 and E12
proteins enhance the expression of TrkB and p21Cip1, whereas
Id2 exerts opposite effects; and (iv) E2A and NeuroD proteins
bind the TrkB and p21Cip1 promoters; and (v) ectopic expres-
sion of these bHLH transcriptional factors is able to activate
TrkB expression in the absence of RA. Since they regulate
expression of both a cell cycle inhibitor, p21Cip1, and a neuro-
trophic receptor, TrkB, bHLH proteins would play a key role in
the coordination between cell cycle arrest and neuronal differ-
entiation.
Upregulation of p21Cip1 expression as an early event induced
by RA has been reported by different groups (23, 46), and RA
transcriptionally upregulates p21Cip1 through an RA-respon-
sive element in the promoter region of p21Cip1 during RA-
induced monocyte differentiation of U937 cells (23). Accord-
ing to these data we show that the RAR-binding site is
important for transcriptional activation of the p21Cip1 pro-
moter by RA. In addition, we have found by ChIP assays that
RAR, the all-trans-RA receptor, binds directly to the RAR
element in the p21Cip1 promoter when SH-SY5Y cells are
treated with RA (unpublished results). Thus, the initial
changes in p21Cip1 expression in SH-SY5Y cells may be directly
mediated by the RA receptor as an early event.
We have shown that p21Cip1 expression suffers a second
burst of induction after 2 days of RA treatment that is quan-
titatively much more important than the early increase and
causes accumulation of hypophosphorylated pRB with a sub-
sequent G1 arrest. Our findings suggest that the accumulation
of hypophosphorylated pRB forms could be a consequence of
the inhibition of Cdk4/cyclin D1 and Cdk2/cyclin E complexes
by binding to increasing amounts of p21Cip1 (and p27Kip1 to a
lesser extent). Elevation of p21Cip1 levels by RA has been
found also in other neuroblastoma cell lines, and ectopic ex-
pression of p21Cip1 was sufficient to produce a cell cycle arrest
in human SK-N-SH-N cells (51), a neuroblastoma cell line
closely related to the SH-SY5Y cells used in our study.
Transcriptional activation of p21Cip1 is mediated by bHLH
proteins and requires the E-box elements of the p21Cip1 pro-
moter. We have shown that TrkB expression is also upregu-
lated in SH-SY5Y cells simultaneously with the second burst of
p21Cip1 expression. It is well known that RA is able to increase
TrkB expression in many neuroblastoma cell lines, including
KCNR, LAR-5, and SH-SY5Y cells (15, 26, 38). On the other
hand, in adult-derived neuronal stem cell cultures (46), the
cellular responses to RA included upregulation of p21Cip1, exit
from the cell cycle, and a subsequent upregulation of neuro-
trophin receptors (TrkA, TrkB, TrkC, and p75NGFR). Nonethe-
less, the molecular mechanisms by which RA activates TrkB
gene transcription were not identified.
Here we show for the first time that E2A proteins bind the
TrkB promoter in vivo. Consistent with this result, overexpres-
sion of E2A proteins clearly increases the TrkB promoter ac-
tivity even in the absence of RA. Moreover, we have also
proved the DNA-binding activity of E2A proteins toward the
p21Cip1 promoter in vivo. The relative efficiencies of ChIP with
the -E47 antibody for both TrkB and p21Cip1 promoters were
slightly higher in RA-treated cells. Considering that the overall
protein levels of E2A are very similar in both cycling and
RA-treated cell extracts, we propose that RA may modulate
the DNA-binding ability of these bHLH proteins, either as a
homodimer or a heterodimer with class II bHLH proteins.
Although E2A proteins form homodimers and bind to E-box
elements in the immunoglobulin heavy-chain enhancer to ac-
tivate B-cell differentiation (44), E proteins have been found to
bind to DNA usually as heterodimers with tissue-specific
bHLH proteins (12, 35, 40, 42). Inner-ear sensory neurons
depend on NeuroD as a tissue-specific bHLH protein for sur-
vival during differentiation, and mice lacking NeuroD produced
inner-ear sensory neurons that failed to express the neurotro-
phin receptors TrkB and TrkC, suggesting that the ability of
NeuroD to support neuronal survival may involve the regula-
tion of neurotrophin receptor expression (17). In addition, RA
has been shown to increase NeuroD expression in both SH-
SY5Y cells (24) and neural stem cells from adult rat hippocam-
pus (46). Accordingly, we have detected the presence of ec-
topically expressed FLAG-NeuroD on both the TrkB and
p21Cip1 promoters, suggesting that this tissue-specific bHLH
protein could be involved in regulating TrkB and p21Cip1 ex-
pression in SH-SY5Y cells.
Loss of Id proteins from proliferating zones of the brain,
which occurs during early neurogenesis, plays an important
role in initiating expression of neuronal genes and differenti-
ation (27). Oligodendrocyte precursor cells forced to overex-
press Id2 exhibit a substantially attenuated ability to differen-
tiate. On the other hand, Id2/ oligodendrocytes show
premature differentiation in mice (53). We have found that, in
agreement with its negative role in regulating transcription
activity of bHLH proteins, Id2 is also capable of inhibiting the
transcription of TrkB during RA treatment.
In addition to their role in regulating differentiation, Id
proteins play active roles in cell cycle regulation (37). In vivo,
neuroblasts derived from Id1/ Id3/ fetal brain exit pre-
maturely from the cell cycle, accompanied by elevated expres-
sion of p16Ink4a and p27Kip1 (27). Further, Id2/ mammary
epithelial cells are defective in proliferation during pregnancy
and exhibit elevated levels of p21Cip1 and p27Kip1 expression
(33). According to this, overexpression of Id2 in RA-treated
SH-SY5Y cells was able to prevent activation of the p21Cip1
promoter, and produced an abnormal S-phase entry.
Several studies have demonstrated that pRB is a key regu-
lator of neuronal development (7). In this regard, the expres-
sion of neuronal differentiation markers such as II tubulin,
TrkA, TrkB, and p75NGFR is significantly decreased in pRb-
deficient embryos (21). On the other hand, pRB and Id2 coun-
teract functionally by a direct physical interaction. Id2 is able to
bind pRb and abolish its growth-suppressing activity (13, 20),
whereas a constitutively active pRB mutant is able to suppress
Id2 overexpression-mediated effects in neuron-specific gene
expression and apoptosis (48). According to this role in bHLH-
mediated gene expression, we have found that a nonphosphor-
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ylatable pRb mutant is able to activate TrkB and p21Cip1 ex-
pression in SH-SY5Y cells (unpublished results).
The close relationship between Id proteins and the regula-
tion of cell proliferation and differentiation suggests that these
inhibitory proteins may play a key role connecting RA signals
to bHLH protein activity. Myc has been involved in transcrip-
tional activation of Id2 (8, 20), and RA causes a dramatic
decrease in Myc levels as a very early response in SH-SY5Y
cells (24). Although other factors controlling Id gene expres-
sion may be involved in human neuroblastoma (50, 52), Myc
downregulation could explain the subsequent decrease of Id2
caused by RA in SH-SY5Y cells, thus producing an increase in
bHLH protein activity. Ectopic overexpression of E2A pro-
teins in SH-SY5Y cells was not sufficient to cause a clear delay
in cell cycle entry in the absence of RA (our unpublished data),
suggesting that cell cycle arrest would involve both upregula-
tion of bHLH-mediated p21Cip1 transcription and release of
hypophosphorylated pRB by Id2 downregulation.
Similar coordination mechanisms involving bHLH proteins
in osteoblast differentiation have recently been proposed by
Funato et al. (9). Although proof for a direct protein-DNA
interaction was not provided, these authors found that E2A
proteins induce transcription of p21Cip1 and fibroblast growth
factor receptor 3 (FGFR3), which is important for osteoblast
differentiation. In addition, bHLH negative regulators includ-
ing Id1, Id3, and Twist inhibited the transcriptional activation
of both p21Cip1 and FGFR3.
In conclusion, our findings show that bHLH proteins acti-
vate expression of genes that lead to cell cycle arrest and
differentiation in a coordinate way. This coordination would be
mediated by the fact that bHLH proteins bind the promoter of
p21Cip1, a cell cycle exit gene, and the promoter of TrkB, a gene
encoding a key tyrosine kinase receptor for differentiation and
survival in the nervous system.
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